Recent Updates
Recently added Catalysts

Tarlatamab treatment

Phase 2

Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract | Small molecule | Oncology |Pulmonx Corporation|Last Updated: Aug 26, 2026

Target and mechanism

Molecular targetDLL3, CD3E, CD3G, CD3D
Target classBinding Agent
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

Clinical trial landscape

Tarlatamab treatment · 1 trial · 1 indication

Phase 2 1
NCT07788365Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept StudyDiagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract
NOT YET_RECRUITING20 Analytics
PHASE2NOT YET_RECRUITING
Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study
Diagnosis of Neuro-endocrine Carcinoma of the Gynecological TractUnlock trial analytics

Study Endpoints

Primary Endpoints

Progression free survival (PFS) at month 9, defined as the time from first administration of Tarlatamab to progression
at 9 months
Overall Survival (OS)
24 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TarlatamabEXPERIMENTAL -

Interventions

NameTypeDescription
Tarlatamab treatmentDRUGTarlatamab will be administered as an IV infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1 or 2. 2. A confirmed diagnosis of neuro-endocrine carcinoma of the gynecological tract including small cell cervical cancer or other high-grade neuro-endocrine carcinoma from the vulva or vagina. Mixed...

Countries:France
Unlock Eligibility Criteria